Advertisement

Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor

Chapter
First Online:
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 212)

Abstract

The Bruton’s tyrosine kinase (BTK) is an essential in the B-cell receptor (BCR) signaling pathway which was identified as crucial in the pathogenesis of B-cell malignancies. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of distinct B-cell malignancies. To overcome off-target side effects of and emerging resistances to ibrutinib, more selective second-generation BTK inhibitors were developed. Acalabrutinib is a novel second-generation BTK inhibitor and has shown promising safety and efficacy profiles in phase 1/2 clinical trials in patients with relapsed CLL and pretreated MCL. Recently, acalabrutinib was approved by the FDA for treatment of adult patients with MCL who received at least one prior therapy. However, clinical trials on a direct comparison between ibrutinib and acalabrutinib and on combination treatment options with other agents as CD20 antibodies are warranted.

Keywords

Acalabrutinib Bruton’s tyrosine kinase Hematologic malignancies 
This is a preview of subscription content, log in to check access.

References

  2. AstraZeneca (2017a) Prescribing information of CALQUENCE (acalabrutinib) [monograph on the internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf
  3. AstraZeneca (2017b) S FDA approves AstraZeneca’s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma [monograph on the internet]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html
  4. Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A (2017) Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 363:240–252CrossRefPubMedGoogle Scholar
  5. Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M, Winiarska M (2015) B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Mol Dis 55:255–265CrossRefPubMedGoogle Scholar
  6. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:323–332CrossRefPubMedGoogle Scholar
  7. ClinicalTrials.gov (2017) Acalabrutinib (ACP-196) clinical trials [monograph on the internet]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=acalabrutinib&cntry1=&state1=&Search=Search
  8. Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS (2017) Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31:2075–2084CrossRefPubMedPubMedCentralGoogle Scholar
  9. FDA (2017) FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma [monograph on the internet]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm
  10. Golay J, Ubiali G, Introna M (2017) The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica 102:e400–e403CrossRefPubMedPubMedCentralGoogle Scholar
  11. Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC (2016) Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma. PLoS ONE 11:e0159607CrossRefPubMedPubMedCentralGoogle Scholar
  12. Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA (2017) The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic Leukemia. Clin Cancer Res 23:2831–2841CrossRefPubMedGoogle Scholar
  13. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB (2017) Diagnosis and Management of Waldenstrom Macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol 3:1257–1265CrossRefPubMedPubMedCentralGoogle Scholar
  14. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA (2016) Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127:1559–1663CrossRefPubMedGoogle Scholar
  15. Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, Chiorazzi N, Izumi R, Ulrich R, Lannutti BJ, Wiestner A, Herman SEM (2017) Combined BTK and PI3Kdelta inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model. Clin Cancer Res 23:5814–5823CrossRefPubMedGoogle Scholar
  16. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R (2017) Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 129:2224–2232CrossRefPubMedPubMedCentralGoogle Scholar
  17. Patel VK, Lamothe B, Ayres ML, Gay J, Cheung J, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V (2017) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: Similarity of on-target effects to ibrutinib and rationale for combination therapy. LeukemiaGoogle Scholar
  18. Robak P, Robak T (2017) Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26:1249–1265CrossRefPubMedGoogle Scholar
  19. Thompson PA, Burger JA (2017) Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs 1–12Google Scholar
  20. Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Gine E, Navarro A, Bea S, Campo E, Lopez-Guillermo A, Lopez-Guerra M, Roue G, Colomer D, Perez-Galan P (2017) The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-kappaB mutational status. Haematologica 102:e447–e451CrossRefPubMedPubMedCentralGoogle Scholar
  21. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G (2016) A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127:411–419CrossRefPubMedPubMedCentralGoogle Scholar
  22. Wu J, Liu C, Tsui ST, Liu D (2016a) Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9:80CrossRefPubMedPubMedCentralGoogle Scholar
  23. Wu J, Zhang M, Liu D (2016b) Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 9:21CrossRefPubMedPubMedCentralGoogle Scholar
  24. Wu J, Zhang M, Liu D (2017) Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget 8:7201–7207PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hematology, Oncology and RheumatologyHeidelberg UniversityHeidelbergGermany
  2. 2.Institute of Pathology, Heidelberg UniversityHeidelbergGermany

Personalised recommendations

Cite chapter

Buy options